dc.contributor.author | Cüre, Erkan | |
dc.contributor.author | Kırbaş, Aynur | |
dc.contributor.author | Tümkaya, Levent | |
dc.contributor.author | Cüre, Medine Cumhur | |
dc.contributor.author | Şahin, Osman Zikrullah | |
dc.contributor.author | Kalkan, Yıldıray | |
dc.contributor.author | Yüce, Süleyman | |
dc.contributor.author | Altuner, Durdu | |
dc.date.accessioned | 2020-12-19T20:03:02Z | |
dc.date.available | 2020-12-19T20:03:02Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | Cure, E., Kirbas, A., Tumkaya, L., Cure, M. C., Sahin, O. Z., Kalkan, Y., Yuce, S., & Altuner, D. (2014). Effect of infliximab against cisplatin-induced nephrotoxicity. Saudi medical journal, 35(9), 953–958. | en_US |
dc.identifier.issn | 0379-5284 | |
dc.identifier.uri | https://hdl.handle.net/11436/3067 | |
dc.description | cure, erkan/0000-0001-7807-135X; Cure, Medine Cumhur/0000-0001-9253-6459 | en_US |
dc.description | WOS: 000343245700003 | en_US |
dc.description | PubMed: 25228176 | en_US |
dc.description.abstract | Objectives: To investigate whether infliximab (Ib), an inhibitor of tumor necrosis factor alpha (TNF-alpha), prevents cisplatin (Cis)-induced nephrotoxicity. Methods: the study was performed in the Department of Internal Medicine, Recep Tayyip Erdogan University, Rize, Turkey, between November 2012 and May 2013. Thirty male Wistar albino rats were divided into 3 groups, a control group, a Cis group, and a Cis+Ib group. the animals of the Cis group were injected with a single dose (7 mg/kg) of Cis intraperitoneally. the animals of the Cis+Ib group were injected with a single dose (7 mg/kg) of Ib 72 hours prior to Cis injection. Results: the TNF-alpha, interleukin-1 beta (IL-1 beta), nitric oxide (NO) and adenosine deaminase (ADA) levels of the Cis group were higher than both the control group TNF-alpha (p<0.001), IL-1 alpha (p<0.001), NO (p<0.001) and ADA (p<0.001), and the Cis+Ib group TNF-alpha (p<0.001), IL-1 beta (p<0.001), NO (p<0.001), and ADA (p=0.003). Histopathological examination revealed extensive damage in the Cis group, while the damage in the Cis+Ib group was lower. While the carbonic anhydrase II (CA-II) level of the Cis group was lower than both groups, it was similar in the Cis+Ib and the control groups. Conclusion: Infliximab acts against Cis-induced nephrotoxicity by a strong inhibition of TNF-alpha. Additionally, the combination of these 2 drugs does not obviously change the level of CA-II. | en_US |
dc.description.sponsorship | RTEU Bilimsel Arastirmalar Proje Birimi (BAP)Recep Tayyip Erdogan University [2012.106.01.5] | en_US |
dc.description.sponsorship | Disclosure. Funding for this study was received from RTEU Bilimsel Arastirmalar Proje Birimi (BAP), Project No. 2012.106.01.5. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Saudi Med J | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Carboniz-anhdrase-II | en_US |
dc.subject | Adenosine-deaminase | en_US |
dc.subject | Ischemia reperfusion | en_US |
dc.subject | Rheumatoid arthritis | en_US |
dc.title | Effect of infliximab against cisplatin-induced nephrotoxicity | en_US |
dc.type | article | en_US |
dc.contributor.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.contributor.institutionauthor | Cüre, Erkan | |
dc.contributor.institutionauthor | Kırbaş, Aynur | |
dc.contributor.institutionauthor | Tümkaya, Levent | |
dc.contributor.institutionauthor | Cüre, Medine Cumhur | |
dc.contributor.institutionauthor | Şahin, Osman Zikrullah | |
dc.contributor.institutionauthor | Kalkan, Yıldıray | |
dc.contributor.institutionauthor | Yüce, Süleyman | |
dc.contributor.institutionauthor | Altuner, Durdu | |
dc.identifier.volume | 35 | en_US |
dc.identifier.issue | 9 | en_US |
dc.identifier.startpage | 953 | en_US |
dc.identifier.endpage | 958 | en_US |
dc.relation.journal | Saudi Medical Journal | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |